Portfolio Finder


AYOXXA is a biotechnology company that has developed the LUNARISTM platform, a revolutionary technology for the multiplex analysis of proteins. The business model is comparable to that of iTunes. Like iPhones, AYOXXA's biochips can be used in a whole range of analyses. The biomarkers are provided by AYOXXA itself and also by cooperation partners.
At the core of this patented technology are the so-called "In-situ Encoded Bead Arrays" (IEBA), which enable the simultaneous analysis of different proteins in an accurate, cost-effective and very small sample size. These novel biochips are used in pharmacological screening and biomedical research. Since 2018, more than 20 LUNARISTM readers have been placed with international pharmaceutical companies and AYOXXA generates growing revenues from the sale of consumables.

Added to portfolio 22. Dec 2011

ChromoTek (Exit)

ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.

Sector: R & D Tools
HTGF-Manager: Dr. Bernd Goergen
In portfolio 27. Apr 2010 – 09. Oct 2020


denovoMATRIX develops and manufactures biomimetic coatings for the cultivation of human stem cells. Our focus is on enabling culture conditions for stem and primary cells closer to the natural conditions found in the body. Our products offer a biologically relevant solution, which is both chemically defined, and modular for adapting to specific applications. Our vision is to enable human biology in vitro, beginning with Life Science research and onwards to cell therapies of the future.

HTGF-Manager: Dr. Fabian Mohr
Added to portfolio 15. Oct 2018


DyNAbind is offering innovative drug discovery products and services based on its proprietary Dynamic DNA-Encoded Library (D-DEL) technology platform. With D-DEL, DyNAbind can simultaneously screen hundreds of millions of compounds against a target protein. Follow-up hit triage is also rapid, thanks to the Binding Profiler system for hit validation. Altogether, DyNAbind’s platform delivers higher-quality, more relevant medicinal chemistry starting points at about 10 times the speed of conventional approaches.

Sector: R & D Tools
HTGF-Manager: Dr. Fabian Mohr
Added to portfolio 17. Apr 2019

Lino Biotech

lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family offices. lino offers industry partners and researchers a unique way to study molecular interactions in living cells and crude biosystems.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 03. Mar 2020

m2p-labs (Exit)

m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated cultivation RoboLector® platforms, an integration of the BioLector® tool into a liquid handling system.
Proprietary online monitoring technology increases the number and the information content of microbial experiments, either aerobic, microaerophilic, or strictly anaerobic. Experiments can be conducted with excellent efficiency and high quality at low costs in microscale.

HTGF-Manager: Marco Winzer
In portfolio 21. Jun 2006 – 11. Nov 2020


A well-rounded life science company, OakLabs' singular goal is to support scientific companies and institutions with groundbreaking revelations, perhaps most notably in the realm of drug development, companion diagnostics (CDx) and development of IEC 62304 compliant medical device software.

The skilled team of quantum physicists and biochemists at OakLabs have revitalized the process of drug development with a new and efficient approach to patient selection in clinical trials. Their groundbreaking technique entails the use of an innovative algorithm to develop complex biomarker signatures which can accurately predict (non-)responders for specific drugs with superior accuracy. Not only does this lead to success in clinical trials, it can also help to gain market shares in a competitive environment, offering tangible results for continued market success after approval.

Sector: R & D Tools
HTGF-Manager: Ulrike Kalapis
Added to portfolio 28. Dec 2011


PEPperPRINT produces customized ultra-high density peptide microarrays and uses individualized peptide libraries for drug development, antibody characterization, and protein biomarker discovery.

Sector: R & D Tools
HTGF-Manager: Dr. Bernd Goergen
Added to portfolio 26. Feb 2010


PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 01. Dec 2014


PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) - based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.

HTGF-Manager: Dr. Fabian Mohr
Added to portfolio 06. Feb 2017

Resolve Biosciences

Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to create three-dimensional maps of molecular activity in living cells.

HTGF-Manager: Dr. Caroline Fichtner
Added to portfolio 27. Nov 2020


Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 14. Nov 2016